ABSTRACT: Accelerated-Intensified Cyclophosphamide, Epirubicin,
and Fluorouracil Compared With Standard CEF in Metastatic Breast
Cancer Patients: Results of a Multicenter, Randomized Phase III
Study of the Italian Gruppo Oncologico Nord-Ouest-Mammella Inter
PURPOSE: To evaluate whether an accelerated-intensified cyclophosphamide,
epirubicin, and fluorouracil (CEF) chemotherapy regimen with
the support of granulocyte colony-stimulating factor (G-CSF)
induces a higher activity and efficacy compared with standard
CEF in metastatic breast cancer patients.
CONCLUSION: In metastatic breast cancer patients, an 80% increase
in dose-intensity of the CEF regimen, obtained by both acceleration
and dose intensification, does not improve the activity and the
efficacy compared with a standard dose-intensity CEF regimen.